Candidate gene and genome-wide association studies (GWAS) have identified 15 independent genomic regions associated with bladder cancer risk. In search for additional susceptibility variants, we followed up on four promising single nucleotide polymorphisms (SNPs) that had not achieved genome-wide significance in 6,911 cases and 11,814 controls (rs6104690, rs4510656, rs5003154 and rs4907479, P<1×10(-6)), using additional data from existing GWAS datasets and targeted genotyping for studies that did not have GWAS data. In a combined analysis, which included data on up to 15,058 cases and 286,270 controls, two SNPs achieved genome-wide statistical significance: rs6104690 in a gene desert at 20p12.2 (P=2.19×10(-11)) and rs4907479 within the MCF2L gene at 13q34 (P=3.3×10(-10)). Imputation and fine-mapping analyses were performed in these two regions for a subset of 5,551 bladder cancer cases and 10,242 controls. Analyses at the 13q34 region suggest a single signal marked by rs4907479. In contrast, we detected two signals in the 20p12.2 region - the first signal is marked by rs6104690 and the second signal is marked by two moderately correlated SNPs (r(2)=0.53), rs6108803 and the previously reported rs62185668. The second 20p12.2 signal is more strongly associated with the risk of muscle-invasive (T2-T4 stage) compared to non-muscle-invasive (Ta, T1 stage) bladder cancer (case-case P<0.02 for both rs62185668 and rs6108803). Functional analyses are needed to explore the biological mechanisms underlying these novel genetic associations with risk for bladder cancer.